export default function PublicationsPage() {
  return (
    <div className="container mx-auto max-w-4xl px-4 py-12">
      <h1 className="text-3xl font-bold mb-8">Publications</h1>
      <div className="space-y-8">
        <div className="text-justify">
          <p className="mb-8">
            1: Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, Farolfi A, Koerber SA, Debus J, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Henkenberens C, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Bartenstein P, Hruby G, Scharl S, Wiegel T, Emmett L, Arnoux A, Schmidt-Hegemann NS. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer. JAMA Netw Open. 2023 May 1;6(5):e2314748. doi: 10.1001/jamanetworkopen.2023.14748. PMID: 37219907; PMCID: PMC10208140.
          </p>
          <p className="mb-8">
            2: Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):558-567. doi: 10.1007/s00259-023-06438-3. Epub 2023 Sep 22. PMID: 37736808; PMCID: PMC10774185.
          </p>
          <p className="mb-8">
            3: Janbain A, Farolfi A, Guenegou-Arnoux A, Romengas L, Scharl S, Fanti S, Serani F, Peeken JC, Katsahian S, Strouthos I, Ferentinos K, Koerber SA, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SK, Grosu AL, Ceci F, Henkenberens C, Kroeze SG, Guckenberger M, Belka C, Bartenstein P, Hruby G, Emmett L, Omerieh AA, Schmidt-Hegemann NS, Mose L, Aebersold DM, Zamboglou C, Wiegel T, Shelan M. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study. JMIR Cancer. 2024 Sep 20;10:e60323. doi: 10.2196/60323. PMID: 39303279; PMCID: PMC11452751.
          </p>
          <p className="mb-8">
            4: Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Koerber SA, Debus J, Peeken JC, Vogel MME, Kroeze SGC, Guckenberger M, Krafcsik M, Hruby G, Emmett L, Schmidt-Hegemann NS, Trapp C, Spohn SKB, Henkenberens C, Mayer B, Shelan M, Aebersold DM, Thamm R, Wiegel T. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiother Oncol. 2024 May;194:110215. doi: 10.1016/j.radonc.2024.110215. Epub 2024 Mar 7. PMID: 38458259.
          </p>
          <p className="mb-8">
            5: Trapp C, Aebersold DM, Belka C, Casuscelli J, Emmett L, Eze C, Fanti S, Farolfi A, Fendler W, Grosu AL, Guckenberger M, Hruby G, Kirste S, Koerber SA, Kroeze S, Peeken JC, Rogowski P, Scharl S, Shelan M, Spohn SKB, Strouthos I, Unterrainer L, Vogel M, Wiegel T, Zamboglou C, Schmidt-Hegemann NS. Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3770-3781. doi: 10.1007/s00259-024-06802-x. Epub 2024 Jun 28. PMID: 38940843; PMCID: PMC11445306.
          </p>
          <p className="mb-8">
            6: Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA â‰¥ 0.2 ng/ml. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2529-2536. doi: 10.1007/s00259-023-06185-5. Epub 2023 Mar 11. PMID: 36905411; PMCID: PMC10250454.
          </p>
          <p className="mb-8">
            7: Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Morganti AG, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother Oncol. 2023 Jul;184:109678. doi: 10.1016/j.radonc.2023.109678. Epub 2023 May 3. PMID: 37146766.
          </p>
          <p className="mb-8">
            8: Zamboglou C, Staus P, Wolkewitz M, Peeken JC, Ferentinos K, Strouthos I, Farolfi A, Koerber SA, Vrachimis A, Spohn SKB, Aebersold DM, Grosu AL, Kroeze SGC, Fanti S, Hruby G, Wiegel T, Emmett L, Hayoz S, Ceci F, Guckenberger M, Belka C, Schmidt-Hegemann NS, Ghadjar P, Shelan M. Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography-guided Salvage Radiotherapy Following Prostatectomy. Eur Urol Focus. 2024 Nov 27:S2405-4569(24)002
          </p>
        </div>
      </div>
    </div>
  )
} 